what are real-life Challenges in implementing new therapeutics in mRCC management?
In this episode of mRCC DoctoLIVE series, we will be questioning what are challenges in implementing new therapeutics in metastatic renal cell carcinoma in 2022.Fill in the form below if you are interested in attending our next DoctoLIVE - Episode 1: mRCC FRANCE Live Session, and we will send you event's details.
You can also submit your own questions, we will incorporate them into the live discussion.
EPISODE 1
mRCC FRANCE Live session
Tuesday 22nd of March 2022
at 3PM CET / 9AM EST / 6AM PST / 2PM GMT
Our guest is Dr. Jean CHIDIAC, a French medical oncologist, in charge of the Oncology Unit at Louis Mourier Hospital in Colombes, France. He is co-president of the 3C. His fields of expertise are breast, kidney, urological, gynecological, ovarian, digestive and thoracic cancers. He is also author of several articles.
Interviewed by Geoffroy CORNETTE from our APLUSA office in Paris
DoctoLIVE: A new opportunity to get answers to your questions directly from actual practitioners, all organized by APLUSA
Why DoctoLIVE? 15 minutes of an HCP’s time booked by AplusA to answer your practical questions, live.
DoctoLIVE is your window to real-world challenges in real-life healthcare practice, from an actual healthcare practioner's perspective.
DoctoLIVE offers you a 15-minute open-mic discussion featuring a different HCP every session, answering your questions related to real-life treatment experiences. These discussions will be held in English.
We will cover how to implement new therapeutics in actual practice, uncover pain points and discuss areas for improvement.